Lundbeck and the FDA have established a comprehensive Risk Evaluation and Mitigation Strategy (REMS) to manage the risk of permanent vision loss associated with the product.

• 灵北制药公司和FDA已形成了一个综合性风险评估和降低策略（REMS），控制与该药品使用相关的永久性视力丧失的风险。